Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Non-invasive angina treatment close to approval:

This article was originally published in Clinica

Executive Summary

Following the completion of initial bench trials, CPC of America intends to submit a premarket approval application in the US within six months for its counter-pulsation device for treating angina. The Sarasota, Florida-based company plans to carry out a clinical study to see how well the device, called CPCA2000, relieves angina or chest pain in patients who did not respond to conventional therapy. The treatment, which uses external pressure cuffs to force blood back through blocked arteries, could be an alternative to angioplasty and surgery.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts